OCT-1, ABCB1, and ABCG2 Expression in Imatinib-Resistant Chronic Myeloid Leukemia Treated with Dasatinib or Nilotinib

This study explored drug transporter expression levels and their impact on clinical response to imatinib and second-generation tyrosine kinase inhibitors (TKIs) in imatinib- resistant chronic myeloid leukemia (CML). Imatinib-resistant chronic phase CML patients treated with dasatinib (n=10) and nilo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yeo-Kyeoung, Lee, Seung-Shin, Jeong, Sung-Hoon, Ahn, Jae-Sook, Yang, Deok-Hwan, Lee, Je-Jung, Shin, Myung-Geun, Kim, Hyeoung-Joon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chonnam National University Medical School 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276791/
https://www.ncbi.nlm.nih.gov/pubmed/25568846
http://dx.doi.org/10.4068/cmj.2014.50.3.102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4276791/
https://www.ncbi.nlm.nih.gov/pubmed/25568846
http://dx.doi.org/10.4068/cmj.2014.50.3.102

Ejemplares similares